argenx stock targets oral therapies with $1.15 billion deal
Published on 11/10/2026 at 10:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDeal broadens Argenx's pipeline
- Argenx agreed to acquire Unnatural Products for an upfront cash payment of 550 million US dollars plus up to 595 million US dollars tied to development and regulatory milestones.
- The transaction is expected to close by the end of 2026 and would establish Santa Cruz as Argenx's peptide discovery hub.
- The deal combines Unnatural Products' macrocyclic peptide platform with Argenx's antibody engineering and clinical development capabilities.
Argenx agreed on Monday, November 9, 2026, to acquire Unnatural Products, Inc. for total potential consideration of up to 1.15 billion US dollars. The immunology company said the transaction will add a macrocyclic peptide discovery engine to its antibody engineering capabilities.
GlobeNewswire reported that Argenx already owns a minority stake in Unnatural Products and will acquire the remaining shares. The agreement builds on more than two years of collaboration and investment between the companies.
Transaction terms and strategic scope
Argenx will pay 550 million US dollars upfront from cash on hand. A further 595 million US dollars is contingent on specified development and regulatory milestones, so the full consideration depends on the progress of programs that have yet to reach those milestones.
The boards of both companies have approved the agreement. Closing is expected by the end of 2026, subject to customary closing conditions. Until completion, the transaction remains subject to those conditions and the milestone payments are not guaranteed.
Unnatural Products will continue operating from its Santa Cruz, California, site after closing. The site is intended to become Argenx's home for peptide discovery, while the Unnatural Products team and leadership continue to lead discovery work within a strategic framework agreed with Argenx.
Chief Executive Officer Karen Massey said the platform is complementary to Argenx's antibody engineering and could create new options for oral and long-acting medicines. Argenx said its clinical development and commercial capabilities would be applied to advance potential medicines for serious immune-mediated diseases. Those comments describe the intended strategic benefit rather than an approved product or established revenue stream.
Stock context for investors
Argenx stock traded at 854.90 euros on Lang & Schwarz at 10:33 CET on Tuesday, November 10. The quote provides an intraday reference for investors as the deal moves through its expected year-end closing process.
Argenx at a glance
- Company: argenx SE
- ISIN: NL0010832176
- Lang & Schwarz quote: 854.90 euros at 10:33 CET on November 10, 2026
- Transaction: Unnatural Products acquisition for up to 1.15 billion US dollars
- Expected closing: By the end of 2026, subject to customary closing conditions
European biotechnology investors will also track the broader AEX market environment as the transaction advances.
For further coverage, see More news and analyses on argenx stock.
